The estimated Net Worth of Gonzalez David Angulo is at least 743 千$ dollars as of 21 December 2020. Mr Angulo owns over 1,600 units of Scynexis Inc stock worth over 33,292$ and over the last 9 years he sold SCYX stock worth over 0$. In addition, he makes 709,663$ as Chief Medical Officer at Scynexis Inc.
Mr has made over 11 trades of the Scynexis Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of SCYX stock worth 10,000$ on 21 December 2020.
The largest trade he's ever made was buying 36,950 units of Scynexis Inc stock on 29 June 2016 worth over 82,029$. On average, Mr trades about 5,102 units every 84 days since 2015. As of 21 December 2020 he still owns at least 23,780 units of Scynexis Inc stock.
You can see the complete history of Mr Angulo stock trades at the bottom of the page.
David Gonzalez Angulo is the Chief Medical Officer at Scynexis Inc.
As the Chief Medical Officer of Scynexis Inc, the total compensation of Mr Angulo at Scynexis Inc is 709,663$. There are 2 executives at Scynexis Inc getting paid more, with Dr. Marco Taglietti having the highest compensation of 991,270$.
Mr Angulo is 56, he's been the Chief Medical Officer of Scynexis Inc since . There are 11 older and 4 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
Gonzalez's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302.
Over the last 11 years, insiders at Scynexis Inc have traded over 4,708,140$ worth of Scynexis Inc stock and bought 2,173,590 units worth 13,469,713$ . The most active insiders traders include Advisors Llcperceptive Life...、Patrick Machado、Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of 64,694$. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth 225,000$.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: